Company Overview

Zynex, Inc. is a U.S.-based medical device company focused on the development, manufacturing, and marketing of non-invasive electrotherapy products for pain management, rehabilitation, and neurological monitoring. The company primarily operates in the medical devices and healthcare technology industries, with a core emphasis on prescription-based devices used in clinical and home settings. Zynex generates the majority of its revenue from the sale and rental of electrotherapy devices and related consumable supplies reimbursed through insurance providers.

The company’s primary business lines include pain management electrotherapy devices and, to a smaller extent, patient monitoring technologies. Zynex serves healthcare providers, including physicians, physical therapists, and pain management clinics, as well as patients prescribed its devices. Its strategic positioning centers on vertically integrated operations, in-house manufacturing, and a direct sales model, which management states provides cost control and regulatory oversight advantages. Zynex was founded in 1996 and initially focused on neurological diagnostics before pivoting in the early 2000s toward electrotherapy for pain management, which has since become its dominant revenue driver.

Business Operations

Zynex operates through two primary business segments: Pain Management and Patient Monitoring. The Pain Management segment accounts for the vast majority of company revenue and includes products such as functional electrical stimulation (FES), neuromuscular electrical stimulation (NMES), transcutaneous electrical nerve stimulation (TENS), and interferential devices. Revenue is generated through device sales, recurring monthly supplies, and insurance reimbursement, primarily from private insurers and government payers.

The Patient Monitoring segment focuses on technologies designed to improve maternal and neurological care, including blood volume monitoring and seizure detection systems. While commercially launched, this segment has historically generated limited revenue compared to pain management. Zynex conducts manufacturing internally at its facilities in the United States and distributes products primarily through a direct sales force. The company does not rely on significant joint ventures but operates through wholly owned subsidiaries supporting sales, manufacturing, and research activities.

Strategic Position & Investments

Zynex’s strategic direction emphasizes organic growth within the pain management market, expansion of its sales force, and increased penetration of insurance-covered electrotherapy treatments as alternatives to opioid-based pain therapies. Management has consistently highlighted recurring revenue from supplies and long-term patient relationships as a core strategic objective. The company also invests in research and development to expand its device portfolio and improve reimbursement acceptance.

In addition to internal development, Zynex has invested in expanding its Patient Monitoring technologies, positioning them as longer-term growth opportunities. Notable subsidiaries include Zynex Medical, which handles pain management operations, and Zynex Monitoring Solutions, which oversees monitoring device development and commercialization. The company has historically favored internal investment over large-scale acquisitions, and publicly available filings do not indicate material completed acquisitions in recent years.

Geographic Footprint

Zynex is headquartered in Englewood, Colorado, and its primary operations are concentrated in the United States, which represents the overwhelming majority of revenue. Manufacturing, sales, customer service, and administrative functions are largely domestic, aligning with U.S. regulatory and reimbursement frameworks. The company markets its products nationwide through regional sales representatives and centralized fulfillment operations.

International exposure is limited. While Zynex has indicated the capability to distribute products outside the U.S., public disclosures show minimal revenue contribution from international markets, and no material foreign manufacturing facilities have been reported. As a result, the company’s geographic footprint remains predominantly North American with limited global operational influence.

Leadership & Governance

Zynex was founded by Thomas Sandgaard, who has played a central role in shaping its long-term strategy and operational philosophy, emphasizing cost discipline, vertical integration, and organic growth. Leadership is characterized by long executive tenure and significant insider ownership, which the company states aligns management interests with shareholders.

Key executives include:

• Thomas Sandgaard – Founder, Chairman of the Board, and Chief Executive Officer
• Jon T. Serbousek – Chief Financial Officer
• Andre J. Wessel – President
• Robert S. Ullmann – Chief Operating Officer
• Daniel J. McVay – Chief Legal Officer and Corporate Secretary

The leadership team’s stated strategic vision focuses on expanding access to non-invasive pain therapies, maintaining regulatory compliance, and driving profitability through scalable direct-to-provider distribution.